Aurora Cannabis Inc.

NasdaqCM:ACB 株式レポート

時価総額:US$205.0m

Aurora Cannabis 過去の業績

過去 基準チェック /06

Aurora Cannabisは58.8%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は成長しており、年平均9.6%の割合である。

主要情報

58.84%

収益成長率

70.85%

EPS成長率

Pharmaceuticals 業界の成長5.95%
収益成長率9.64%
株主資本利益率-16.12%
ネット・マージン-22.38%
前回の決算情報31 Dec 2025

最近の業績更新

Recent updates

Seeking Alpha Nov 06

Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy

Summary Aurora Cannabis reported Q2/FY2026 results largely in line with expectations previously outlined by management. High-margin medical cannabis revenue increased by 15% year-over-year and 9% quarter-over-quarter, driven by strong sales in Germany and Poland. On the flip side, sales in Australia declined for a second consecutive quarter due to increasing competition. The disappointing performance resulted in the requirement to take a sizeable impairment charge. While not everything is going according to plan, management remained constructive on the company's near-term outlook and guided for record Adjusted EBITDA in Q3. As a result, I am increasing my price target from $5.65 to $6.30. Given more than 40% upside from current levels and expectations for solid growth in medical cannabis sales, I am upgrading the stock from "Hold" to "Buy". Read the full article on Seeking Alpha
Seeking Alpha Feb 22

Aurora Cannabis: This Phoenix Has Risen From The Ashes (Strong Buy Initiation)

Summary Aurora Cannabis has transformed its margins, market position, and balance sheet over the last few years, and the stock is now highly 'investible'. ACB's strategic focus on the global medical cannabis market has led to gross margin growth and reduced competition, enhancing top and bottom-line results. The stock is trading at an extremely attractive multiple, and we see significant upside if ACB continues to execute and market awareness of the story improves. We initiate coverage on ACB with a 'Strong Buy' rating. Read the full article on Seeking Alpha
Seeking Alpha Aug 08

Aurora Cannabis: Revving Up To Profitability

Summary Aurora Cannabis achieves milestone positive free cash flow for the first time in Q1 FY2025. Strong growth in medical cannabis, particularly in Australia and Europe, positions the company well for future profitability. Potential US rescheduling of cannabis could impact Aurora's stock price and open up opportunities in the US market. Read the full article on Seeking Alpha
Seeking Alpha Oct 17

Aurora launches new cannabis products for adult and medical-use

Aurora Cannabis (NASDAQ:ACB) is trading ~2% higher after it announced its fall lineup of cannabis products. The products include three unique and proprietary strains -Electric Honeydew, Ultra Grape Kush and Organic BC White Grape OG. The fall product release is set to roll out to patients on Aurora Medical starting in October. "This extensive line up of flower innovation was made possible from Aurora's differentiated consumer preference mapping, which uniquely plots evolving cannabis preferences, and the leading work of R&D to develop a portfolio of products with the critical components necessary to compete – intense and exciting aromas, key visual and tactile attributes, and high-potency THC," the company said.
Seeking Alpha Oct 07

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Aurora Cannabis (NASDAQ:ACB) has repurchased approximately C$31.3M (US$23M) principal amount of its convertible senior notes at a 5.45% discount to par value, at a total cost, including accrued interest, of C$29.8M in cash. The purpose of the transaction was to reduce the company's debt and annual cash interest costs. Annual cash interest savings from the repurchases of notes made from Q3 2022 onwards now total approximately C$11.9M. The company's balance sheet remains amongst the strongest in the industry, with approximately $380M of cash and cash equivalents. The company reiterates its expectation of achieving a positive Adjusted EBITDA run rate by December 31, 2022. Shares up 4.5% PM. Also read: Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review
Seeking Alpha Sep 19

Aurora Cannabis Q4 2022 Earnings Preview

Aurora Cannabis (NASDAQ:ACB) is scheduled to announce Q4 earnings results on Monday, September 19th, before market open. The consensus EPS Estimate is -$0.12 and the consensus Revenue Estimate is $38.16M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.  In Q3,  the company boosted it target for annual expenses to C$150M-C$170M by 1H 2023, up from C$60M-$C-80M before. Last quarter, the company saw its Q3 2022 EBITDA net loss narrow 41% to C$12.3M compared to the prior-year period despite a decrease in net revenue. Also Read- Non-medical cannabis sales rose 21% YTD in Canada - Cantor
Seeking Alpha Aug 25

Aurora Cannabis: Don't Let Your Money Go Up In Smoke

Summary Aurora Cannabis has been dead money for years, and the trend is bound to continue. Company is bleeding cash and there's no immediate solution in sight for the impending liquidity problems. We are not happy with the recent acquisition given the declining fundamentals. Expected political changes will provide no catalyst for the stock going forward. Thesis With the recent acquisition, Aurora Cannabis (ACB) is even more of a stock for investors to avoid. The company has historically reported poor financial results despite major acquisitions, and the company is burning through cash rapidly as loan commitments are coming due. We believe that liquidity issues and an unfavorable political environment in the United States will continue to drive this stock price lower over the coming years. Company Overview Aurora Cannabis is a cannabis growing company based in Edmonton, Canada. Aurora operates a network of subsidiaries related to the cannabis industry, and the company owns numerous brands, such as San Rafael '71, Daily Special, CanniMed, Whistler Cannabis Co., and more. These brands create cannabis products for consumer and medical consumption. The stock has had abysmal return for investors, and the stock trades at around $1.675 compared to its historic high above $120 per share only a few years ago. The company now has a valuation of less than $500 million CAD. ACB data by YCharts Abysmal Performance and Returns Aurora Cannabis has had poor financial performance in line with the poor stock price performance in the same time frame. The company is still down ~80% from its 52-week high of $8.69 and the stock price is correlated with the revenue decline. For a growth stock name, the company has actually seen its revenue decline over the past few years, even as the company aggressively acquired competitors. For the recent quarter, revenue has declined 9% YoY and has declined 17% QoQ. In addition, the company has reported a loss of $1 billion CAD in the recent quarter, and according to a report, the recent quarter increased the cumulative net losses of the company to roughly $5.3 billion CAD since 2015. These losses are astronomical, given that the cumulative losses are now 10x the current market capitalization of the company. The poor financial performance should immediately be a red flag to investors, and we believe that there is no immediate catalyst to turn this stock around anytime soon. ACB data by YCharts Liquidity Issues For a company with such large losses, it is not hard to find that the company is exposed to major liquidity issues. In the most recent FY 2021 financial report, the company outlines that ~$494 million CAD are liabilities that are payable between one and three years. In that same time frame, the company reported that there's $332.4 million CAD in cash and cash equivalents, which is substantially below the pending commitments in the next few years. Given the liabilities and the negative earnings, liquidity is risk of the utmost issue, and it is unclear how management plans to navigate through this problem. ACB FY 2021 We believe given management's history, we find it likely that the management will continue to keep the business afloat through dilutive actions and tapping into the debt markets, which will only further add debt to the unprofitable business. As seen below, the diluted shares outstanding for ACB has soared as a result of various acquisitions and financing needs. Just recently, the company announced a major acquisition at a price tag of ~$45 million CAD in cash. Regardless of the potential synergies through the acquisition, we find that the cash burn in addition to constant acquisitions are not recipes for success when the company's fundamentals continue to decline. We don't see that this trend will stop any time soon, and we believe that the company should be avoided at all costs as a result of its frivolous spend and impending liquidity crunch. ACB Average Diluted Shares Outstanding (Annual) data by YCharts Upcoming Political Headwinds
Seeking Alpha Jun 13

Why Did Aurora Cannabis Stock Crash In May; Can It Recover?

Aurora Cannabis plunged 54% at the end of May. This was due to an expensive bought deal offering that came even as the company boasted a net cash position. Management has guided for positive adjusted EBITDA within 3 quarters. The stock is cheap relative to Canadian peers.
Seeking Alpha May 13

Recent Developments Do Not Change Our Stance On Aurora Cannabis

Aurora Cannabis reported decent numbers for the third quarter of fiscal 2022. The company continues to focus on cost savings, which is the latest strategy adopted by Aurora to boost short-term earnings. The recent developments do not materially change our view on Aurora for reasons discussed in this analysis.
Seeking Alpha May 05

Aurora Cannabis: A Train Wreck Desperate For Help

Aurora Cannabis is set to release its third quarter earnings on Thursday, May 12, after market close. Last month, the House passed a bill that is set to legalize cannabis on a federal level, it being one of the few positive catalysts going for the company. Management of Aurora has been sued multiple times, including class-action lawsuits due to misleading investors. Since inception, there has been a dilution of over 96%, with high cash burn and no clear end in sight.
Seeking Alpha Feb 17

Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way

The Canadian cannabis retail market has become oversaturated with producers, imposing pricing pressures and making mistakes more costly. ACB is still reeling from its overspending on acquisitions as it tries to cut OPEX as part of its 2020 business transformation plan. The FY22 Q2 earnings call reported a 10% drop in revenue from the year prior, with much of this loss coming from a 48% decrease in retail cannabis revenue. ACB's management is still failing to unite behind a focused strategy and will continue to fail until they do.

収支内訳

Aurora Cannabis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:ACB 収益、費用、利益 ( )CAD Millions
日付収益収益G+A経費研究開発費
31 Dec 25373-841784
30 Sep 25367-571773
30 Jun 25358-31714
31 Mar 25343161664
31 Dec 24320151644
30 Sep 24296-291623
30 Jun 24278-301603
31 Mar 24270-531564
31 Dec 23266-1081814
30 Sep 23262-1531745
30 Jun 23248-1951675
31 Mar 23224-7931706
31 Dec 22212-1,7481638
30 Sep 22210-1,7571808
30 Jun 22221-1,71817610
31 Mar 22226-1,23318511
31 Dec 21231-38118912
30 Sep 21238-60718813
30 Jun 21245-69219511
31 Mar 21257-2,38720616
31 Dec 20275-2,35924118
30 Sep 20263-3,34230023
30 Jun 20269-3,23134626
31 Mar 20299-1,40537224
31 Dec 19291-1,43039722
30 Sep 19290-38537617
30 Jun 19246-29436515
31 Mar 19168-21132710
31 Dec 18119-722537
30 Sep 18771741875
30 Jun 1855721102
31 Mar 1842-13691
31 Dec 17317450
30 Sep 1723-4310
30 Jun 1718-13250
31 Mar 1713-16190
31 Dec 168-13130
30 Sep 165-1081
30 Jun 161-661
31 Mar 160051
31 Dec 150-341
30 Sep 150-1041

質の高い収益: ACBは現在利益が出ていません。

利益率の向上: ACBは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ACBは利益を出していないが、過去 5 年間で年間58.8%の割合で損失を削減してきた。

成長の加速: ACBの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ACBは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。


株主資本利益率

高いROE: ACBは現在利益が出ていないため、自己資本利益率 ( -16.12% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/25 19:32
終値2026/05/22 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Aurora Cannabis Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17

アナリスト機関
Frederico Yokota Choucair GomesATB Cormark
Tamy ChenBMO Capital Markets Equity Research
Etienne RicardBMO Capital Markets Equity Research